CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (ASX: XJO) managed to deliver another positive week, despite finishing just 0.1% higher on Friday.
Growing global outbreaks of the Delta strain have shaken markets but the S&P/ASX 200 (ASX: XJO) finished just 0.5% lower on Tuesday.
The S&P/ASX 200 (ASX:XJO) strengthened throughout the day to finish 0.8% lower on Monday. Telstra (ASX:TLS) and ANZ (ASX:ANZ) shares are in the news.
The S&P/ASX 200 (ASX: XJO) managed a 0.2% gain on Friday as Rio Tinto (ASX:RIO) and Evolution Mining (ASX:EVN) shares make headlines.
The S&P/ASX 200 (ASX:XJO) fell 0.3% on Thursday as Woolworths (ASX:WOW) and Endeavour (ASX:EDV) shares made headlines.
Shares in healthcare giant CSL Limited (ASX: CSL) have made a strong recovery recently. Here’s what could be driving the share price higher.
The S&P/ASX 200 (ASX: XJO) followed global markets lower to begin the week, falling 1.8%. CBA (ASX:CBA) shares are in the news.
The S&P/ASX 200 (ASX: XJO) finished 0.1% higher on Friday as markets continued to digest the week’s change of heart from the Federal Reserve.
The US Federal Reserve has indicated that interest rate rises are likely to come earlier than expected. What does this mean for ASX shares?
